Mirzakhani Mohsen, Tarrahi Mohammad J, Baghersad Atefe, Maracy Mohammad R
Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan.
Department of Genetics, Diseases Control Center, Ministry of Health and Medical Education, Tehran, Iran.
J Pediatr Hematol Oncol. 2019 May;41(4):303-306. doi: 10.1097/MPH.0000000000001423.
Thalassemia screening instructions in Iran categorizes couples with mean corpuscular volume (MCV)=75 to 80, mean corpuscular hemoglobin (MCH)=26 to 27, hemoglobin A2 (HbA2)<3.5, and hemoglobin fetal (HbF)<3 indices as low-risk couples, and therefore further genetic testing is not obligatory. This study examined the possibility of classifying couples with MCH<26 and MCV≥80 indices in the low-risk group when their HbF was <3 and HbA2 was <3.2.
This was a cross-sectional study. The data included results from cell blood count and HbA2 prenatal diagnosis (PND) and HbF tests taken by 22 health care centers in Esfahan province, central Iran, throughout the years 2012-2016. The inclusion criterion was the registering of MCV, MCH, and PND results of the participants. From the 5804 participants, 5624 individuals were included in the study.
The sensitivity and specificity of the screening program were 99.7 and 53.12, respectively. Ten cases (0.18%) with thalassemia trait had indices MCV≥80 and MCH≥26 including 3 cases (0.05%) with concurrent α and β-thalassemia mutations and 7 cases (0.12%) with HbS mutations. Altogether, 553 subjects (9.83%) had MCV≥80 and MCH<26 indices, and only 1 case (0.018%) was found with β-thalassemia mutations (codon8 (-AA)/WT genotype).
Subjects with MCV≥80, MCH<26, HbA2<3.2, and HbF<3 cell blood count indices could be grouped as low-risk couples if normal HbA2 and HbF values are considered. The results of this study also indicate that there is a chance of missing concurrent α and β-thalassemia or HbS hemoglobinopathies in the current screening program given the fact that genetic testing is not considered for couples with MCV and MCH in the low-risk range. HbF testing could be conducted to prevent these missing cases.
伊朗的地中海贫血筛查指南将平均红细胞体积(MCV)=75至80、平均红细胞血红蛋白(MCH)=26至27、血红蛋白A2(HbA2)<3.5且胎儿血红蛋白(HbF)<3的夫妇列为低风险夫妇,因此无需进行进一步的基因检测。本研究探讨了在HbF<3且HbA2<3.2时,将MCH<26且MCV≥80的夫妇归类为低风险组的可能性。
这是一项横断面研究。数据包括伊朗中部伊斯法罕省22个医疗中心在2012年至2016年期间进行的血细胞计数、HbA2产前诊断(PND)和HbF检测结果。纳入标准是记录参与者的MCV、MCH和PND结果。在5804名参与者中,有5624人被纳入研究。
筛查项目的敏感性和特异性分别为99.7和53.12。10例(0.18%)地中海贫血特征患者的MCV≥80且MCH≥26,其中3例(0.05%)同时存在α和β地中海贫血突变,7例(0.12%)存在HbS突变。共有553名受试者(9.83%)的MCV≥80且MCH<26,仅发现1例(0.018%)β地中海贫血突变(密码子8(-AA)/野生型基因型)。
如果考虑正常的HbA2和HbF值,MCV≥80、MCH<26、HbA2<3.2且HbF<3的血细胞计数指标的受试者可归类为低风险夫妇。本研究结果还表明,鉴于目前的筛查项目未对低风险范围内的MCV和MCH夫妇进行基因检测,存在漏诊同时发生的α和β地中海贫血或HbS血红蛋白病的可能性。可进行HbF检测以防止这些漏诊病例。